{Reference Type}: Journal Article
{Title}: Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing.
{Author}: Oliva S;Genuardi E;Paris L;D'Agostino M;Rogers J;Rota-Scalabrini D;Jacob AP;Patriarca F;Luppi M;Bertazzoni P;Velluti C;Capra A;Saraci E;Rossi M;Allegra A;Mina R;Gentile M;Kirsch IR;Belotti A;Cavo M;Bruno B;Musto P;Boccadoro M;Zamagni E;Gay F;
{Journal}: EClinicalMedicine
{Volume}: 60
{Issue}: 0
{Year}: 2023 Jun
{Factor}: 17.033
{DOI}: 10.1016/j.eclinm.2023.102016
{Abstract}: UNASSIGNED: Limited data are available on the concordance between multiparameter flow cytometry (MFC) and next-generation sequencing (NGS) for minimal residual disease (MRD) detection in a large trial for multiple myeloma (MM) patients.
UNASSIGNED: MRD was explored in the FORTE trial for transplant-eligible MM patients randomised to three carfilzomib-based induction-intensification-consolidation treatments and carfilzomib-lenalidomide (KR) vs R maintenance. MRD was assessed by 8-colour 2nd-generation flow cytometry in patients with ≥very good partial response before maintenance. NGS was performed in case of suspected complete response (CR) in a correlative subanalysis. Biological/prognostic concordance between MFC and NGS, conversion to MRD negativity during maintenance, and 1-year/2-year sustained MRD negativity were explored.
UNASSIGNED: Between September 28, 2015 and December 22, 2021, 2020 samples were available for MFC and 728 for the simultaneous MFC/NGS correlation in the "suspected CR population". Median follow-up was 62 months. Biological agreement was 87% at the 10-5 and 83% at the 10-6 cut-offs. A remarkable prognostic concordance was observed: hazard ratios in MFC-MRD and NGS-MRD-negative vs -positive patients were 0.29 and 0.27 for progression-free survival (PFS) and 0.35 and 0.31 for overall survival, respectively (p < 0.05). During maintenance, 4-year PFS was 91% and 97% in 1-year sustained MFC-MRD-negative and NGS-MRD-negative patients (10-5), respectively, and 99% and 97% in 2-year sustained MFC-MRD-negative and NGS-MRD-negative patients, regardless of treatment received. The conversion rate from pre-maintenance MRD positivity to negativity during maintenance was significantly higher with KR vs R both by MFC (46% vs 30%, p = 0.046) and NGS (56% vs 30%, p = 0.046).
UNASSIGNED: The significant biological/clinical concordance between MFC and NGS at the same sensitivity suggests their possible use in the evaluation of one of the currently strongest predictors of outcome.
UNASSIGNED: Amgen, Celgene/Bristol Myers Squibb, Multiple Myeloma Research Foundation.